StockData

Mosaic ImmunoEngineering Inc. (CPMV) stock

CPMVOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 3/30
$0.33+0.00 (0.00%)

Close on Oct 19, 2026Market cap $2.41MP/E –Yield –

Mosaic ImmunoEngineering r&d expenses

Research and development expenses are spending on new products and technology.

Mosaic ImmunoEngineering's R&D Expenses for the twelve months ending Jun 30, 2026 was $63.66K, down 27.4% year over year. For fiscal 2025 it was $63.98K, down 65.2% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$63.98K-65.2%
FY2024Dec 31, 2024$183.87K-57.8%
FY2023Dec 31, 2023$435.45K-58.5%
FY2022Dec 31, 2022$1.05M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026$15.61K-2.5%
Q1 FY2026CQ1 2026Mar 31, 2026$15.88K+0.5%
Q4 FY2025CQ4 2025Dec 31, 2025$16.13K-0.7%
Q3 FY2025CQ3 2025Sep 30, 2025$16.04K-59.5%
Q2 FY2025CQ2 2025Jun 30, 2025$16.01K-73.6%
Q1 FY2025CQ1 2025Mar 31, 2025$15.80K-76.5%
Q4 FY2024CQ4 2024Dec 31, 2024$16.25K-67.5%
Q3 FY2024CQ3 2024Sep 30, 2024$39.60K-53.4%
Q2 FY2024CQ2 2024Jun 30, 2024$60.71K-50.5%
Q1 FY2024CQ1 2024Mar 31, 2024$67.31K-62.2%
Q4 FY2023CQ4 2023Dec 31, 2023$49.99K-75.9%
Q3 FY2023CQ3 2023Sep 30, 2023$84.93K-59.8%
Q2 FY2023CQ2 2023Jun 30, 2023$122.64K-59.5%
Q1 FY2023CQ1 2023Mar 31, 2023$177.90K-45.7%
Q4 FY2022CQ4 2022Dec 31, 2022$207.02K–
Q3 FY2022CQ3 2022Sep 30, 2022$211.08K–
Q2 FY2022CQ2 2022Jun 30, 2022$302.69K–
Q1 FY2022CQ1 2022Mar 31, 2022$327.66K–

More Mosaic ImmunoEngineering figures

See a number that looks wrong?